MINNEAPOLIS--(BUSINESS WIRE)--Uromedica, Inc. announces today that four new Category I CPT (Current Procedural Terminology) codes have been assigned to their FDA-approved product, ProACT™ Adjustable Continence Therapy for Men and will be effective January 1st, 2022. The new CPT-I codes will be: 53451 (bilateral insertion), 53452 (unilateral insertion), 53453 (removal), and 53454 (percutaneous adjustment of balloon(s) fluid volume).
The ProACT Therapy previously received Category III codes from the Center of Medicare Services in July 2019. Per Jonathan Rubenstein, MD and Mark Painter with the Urology Times: “The reason for the change was that the maturation of data and use of these procedures met the American Medical Association’s criteria to achieve a Category I status.”
“With hundreds of successful commercial implants across the US already, Uromedica is excited about this change to Category I codes and we look forward to helping more men regain their continence,” said Tim Cook, PhD, President and CEO of Uromedica.
About ProACT
The ProACT™ Adjustable Continence Therapy for Men is a minimally invasive surgical treatment option for men who have stress urinary incontinence as a result of radical prostatectomy (removal of the prostate) due to prostate cancer or transurethral resection of the prostate due to prostate enlargement. The ProACT balloons are implanted where the prostate was removed or resected and then filled with fluid to apply pressure and support at the bladder neck. This pressure and support helps protect against accidental leaking of urine that can occur during a sneeze, cough, or physical activity. The implantation procedure can be performed in the Ambulatory Surgical Center (ASC) or Hospital Outpatient setting. After the ProACT procedure is completed, the balloon volume can be easily adjusted in an office setting to best meet patient’s needs for achieving continence.
About Uromedica
Uromedica, Inc. is a privately held, Minnesota-based medical device company that has developed and manufactures a long-term implantable balloon therapy for the treatment of stress urinary incontinence in men and women. ProACT has been implanted in over 11,000 patients worldwide since 2002. Interested physicians or patients may visit www.uromedica-inc.com.
